Pacira BioSciences (PCRX) Earnings Announcement Scheduled

Pacira BioSciences (NASDAQ:PCRX) is set to announce its quarterly earnings report after the market closes on Wednesday, November 6th. Analysts are forecasting that the company will report earnings of $0.72 per share for this quarter.

Recently, Pacira BioSciences disclosed its previous quarterly earnings on Tuesday, July 30th. For that quarter, the company reported earnings of $0.64 per share. This result surpassed analysts' expectations, which were set at $0.53 by $0.11. The company recorded revenue of $178.02 million, exceeding the forecasted revenue of $173.31 million.

Financial Performance of Pacira BioSciences

The company had a net margin of 9.21% and a return on equity of 13.22%. For the current fiscal year, analysts predict that Pacira BioSciences will achieve earnings of $2 per share. Similarly, estimates for the next fiscal year also stand at $2 per share.

Stock Performance Overview

On the stock market, Pacira BioSciences opened at $16.87. The stock has a 50-day simple moving average of $15.29 and a 200-day simple moving average of $21.42. Additionally, the firm maintains a debt-to-equity ratio of 0.67, with a current ratio of 6.82 and a quick ratio of 5.70. The market capitalization of the company is currently at $785.23 million, and it has a price-to-earnings ratio of 11.80, with a beta value of 0.84. Over the past year, Pacira BioSciences has seen a low of $11.16 and a high of $35.95.

Recent Analyst Ratings

Several analysts have revised their ratings for Pacira BioSciences in recent weeks. On August 12th, JPMorgan Chase & Co. maintained an "underweight" rating on the stock, reducing its price target from $45.00 to $10.00. Also, Raymond James downgraded the stock from "outperform" to "market perform" on the same day. Conversely, Jefferies Financial Group raised its price target from $15.00 to $18.00, rating the stock as a "buy" on September 24th. Furthermore, Royal Bank of Canada lifted its price objective from $14.00 to $15.00 while assigning a "sector perform" rating on October 4th. Barclays also changed its rating, moving from "overweight" to "equal weight" and cutting the price target from $38.00 to $25.00 in a report released on July 3rd. Overall, the stock has received two sell ratings, four hold ratings, and five buy ratings, with an average rating of "Hold" according to MarketBeat.

Insider Transactions

In an interesting development, CEO Frank D. Lee purchased 8,264 shares of Pacira BioSciences on August 12th, at an average price of $12.10 per share, totaling about $99,994.40. This purchase increased his total holdings to 107,784 shares, with an estimated value of around $1,304,186.40. This information was disclosed in a filing with the SEC. Over the past three months, insiders have procured a total of 11,176 shares valued at $136,240, representing ownership of 6.40% of the company's stock.

Company Profile of Pacira BioSciences

Pacira BioSciences, Inc. focuses on the development, manufacturing, marketing, distribution, and sales of non-opioid pain management and regenerative health solutions to healthcare providers throughout the United States. Its key products include EXPAREL, an injectable suspension of bupivacaine liposome; ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide; and the iovera system, a non-opioid handheld cryoanalgesia device that delivers controlled doses of cold to targeted nerves.

Earnings, Stocks, Pacira